Division of Vascular and Endovascular Surgery, University of California San Diego, San Diego, CA.
Division of Vascular Surgery and Endovascular Therapy, The Johns Hopkins University, Baltimore, MD.
Ann Vasc Surg. 2023 Jan;88:191-198. doi: 10.1016/j.avsg.2022.07.010. Epub 2022 Jul 31.
Despite many patients undergoing carotid endarterectomy (CEA) being on dual antiplatelet therapy (DAPT) for cardiac or neurologic indications, the impact of such therapy on perioperative outcomes remains unclear. We aim to compare rates of postoperative bleeding, stroke and major adverse events (stroke, death or MI) among patients on Aspirin alone (ASAA) versus DAPT (Clopidogrel and Aspirin).
Patients undergoing CEA for carotid artery stenosis between 2010 and 2021 in the Vascular Quality Initiative (VQI) were included. We excluded patients undergoing concomitant or re-do operations or patients with missing antiplatelet information. Propensity score matching was performed between the 2 groups ASAA and DAPT based on age, sex, race, presenting symptoms, major comorbidities [hypertension, diabetes and coronary artery disease (CAD)], degree of ipsilateral stenosis, presence of contralateral occlusion, as well as preoperative medications. Intergroup differences between the treatment groups and differences in perioperative outcomes were tested with the McNemar's test for categorical variables and paired t-test or Wilcoxon matched-pairs signed-rank test for continuous variables where appropriate. Relative risks with 95% confidence intervals were estimated as the ratio of the probability of the outcome event in the patients treated within each treatment group.
A total of 125,469 patients were included [ASAA n = 82,920 (66%) and DAPT n = 42,549 (34%)]. Patients on DAPT were more likely to be symptomatic, had higher rates of CAD, prior percutaneous coronary intervention or coronary artery bypass grafting, and higher rates of diabetes. After propensity score matching, the DAPT group had an increased rate of bleeding complications (RR: 1.6: 1.4-1.8, P < 0.001) as compared with those on ASAA despite being more likely to receive both drains and protamine. In addition, patients on DAPT had a slight decrease in the risk of in-hospital stroke as compared with patients on ASAA (RR: 0.80: 0.7-0.9, P = 0.001).
This large multi-institutional study demonstrates a modest decrease in the risk of in-hospital stroke for patients on DAPT undergoing CEA as compared with those on ASAA. This small benefit is at the expense of a significant increase in the risk of perioperative bleeding events incurred by those on DAPT at the time of CEA. This analysis suggests avoiding DAPT when possible, during CEA.
尽管许多接受颈动脉内膜切除术(CEA)的患者因心脏或神经系统指征而同时接受双联抗血小板治疗(DAPT),但这种治疗对围手术期结局的影响仍不清楚。我们旨在比较单独使用阿司匹林(ASAA)与 DAPT(氯吡格雷和阿司匹林)的患者在术后出血、中风和主要不良事件(中风、死亡或心肌梗死)方面的发生率。
本研究纳入了 2010 年至 2021 年间在血管质量倡议(VQI)中接受 CEA 治疗的颈动脉狭窄患者。我们排除了同时进行或再次进行手术的患者以及抗血小板信息缺失的患者。根据年龄、性别、种族、就诊症状、主要合并症[高血压、糖尿病和冠状动脉疾病(CAD)]、同侧狭窄程度、对侧闭塞情况以及术前用药,对 ASAA 和 DAPT 两组患者进行倾向性评分匹配。采用 McNemar 检验对分类变量和配对 t 检验或 Wilcoxon 配对符号秩检验(如果适用)比较两组间的治疗差异和围手术期结局差异。使用相对风险比(RR)和 95%置信区间(CI)来估计每个治疗组中患者发生结局事件的概率比。
共纳入 125469 例患者[ASAA 组 n=82920(66%)和 DAPT 组 n=42549(34%)]。与 ASAA 组相比,DAPT 组患者更有可能出现症状,CAD、经皮冠状动脉介入治疗或冠状动脉旁路移植术的发生率更高,糖尿病的发生率也更高。在进行倾向评分匹配后,尽管 DAPT 组更有可能使用引流管和鱼精蛋白,但 DAPT 组的出血并发症发生率更高(RR:1.6:1.4-1.8,P<0.001)。此外,与 ASAA 组相比,DAPT 组患者住院期间中风风险略有降低(RR:0.80:0.7-0.9,P=0.001)。
这项大型多机构研究表明,与单独使用 ASAA 相比,CEA 期间使用 DAPT 的患者住院期间中风风险略有降低。DAPT 组在 CEA 时发生围手术期出血事件的风险显著增加,这是以牺牲小部分获益为代价的。该分析表明,在可能的情况下,CEA 期间应避免使用 DAPT。